LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Arcus Biosciences Inc

Chiusa

SettoreSettore sanitario

9.24 -1.18

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.93

Massimo

9.31

Metriche Chiave

By Trading Economics

Entrata

-18M

-112M

Vendite

2M

28M

EPS

-1.14

Margine di Profitto

-400

Dipendenti

627

EBITDA

-34M

-122M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+170.48% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

90M

1.1B

Apertura precedente

10.42

Chiusura precedente

9.24

Notizie sul Sentiment di mercato

By Acuity

63%

37%

340 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Arcus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 giu 2025, 20:41 UTC

Utili

Adobe Raises Outlook After 2Q Sales Beat

12 giu 2025, 23:50 UTC

Utili

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 giu 2025, 23:50 UTC

Utili

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 giu 2025, 23:50 UTC

Utili

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 giu 2025, 23:48 UTC

Discorsi di Mercato

Gold Steady Amid Geopolitical Risks -- Market Talk

12 giu 2025, 23:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 giu 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 giu 2025, 21:26 UTC

Utili

Friedman Industries 4Q Sales $129.2M >FRD

12 giu 2025, 21:25 UTC

Utili

Friedman Industries 4Q EPS 76c >FRD

12 giu 2025, 21:11 UTC

Utili

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 giu 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

12 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 giu 2025, 20:31 UTC

Utili

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 giu 2025, 20:30 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 giu 2025, 20:15 UTC

Utili

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 giu 2025, 20:15 UTC

Utili

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 giu 2025, 20:14 UTC

Utili

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 giu 2025, 20:07 UTC

Utili

Adobe Raises FY25 Rev and EPS Targets

12 giu 2025, 20:05 UTC

Utili

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Net $1.69B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q EPS $3.94 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Rev $5.87B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Adj EPS $5.06 >ADBE

Confronto tra pari

Modifica del prezzo

Arcus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

170.48% in crescita

Previsioni per 12 mesi

Media 25.29 USD  170.48%

Alto 46 USD

Basso 12 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.01 / 8.75Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

340 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.